



A Discussion of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Hosted by Janice Y. Chyou, MD, FHRS

Article Information:

Article for Discussion: [Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation](#)

Authors: Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, Atar D, Birnie DH, Boriani G, Camm AJ, Conen D.

Publication: The New England Journal of Medicine



Today's Host



Janice Y. Chyou, MD, FHRS
Icahn School of Medicine
at Mount Sinai



Today's Contributors:



**Jonathan P. Piccini, Sr.,
MD, MHS, FHRs
Duke University Medical Center**



**Mintu P Turakhia, MD, MS
iRhythm Technologies
and Stanford University**



Disclosures:

Janice Y. Chyou, MD, FHRS

- **Honoraria/Speaking/Consulting:** McGraw-Hill, American Heart Association
- **Membership, Advisory Committee:** American Heart Association

Jonathan P. Piccini, Sr., MD, MHS, FHRS

- **Research:** Boston Scientific, Bayer Healthcare Pharmaceuticals, AMA, Abbott, Phillips, Element Science, Inc., iRhythm Technologies, NIH
- **Honoraria/Speaking/Consulting:** Biotronik, AbbVie, LivaNova, Boston Scientific, Phillips, Medtronic, Electrophysiology Frontiers, Abbott, UpToDate, Inc., Sanofi, Milestone Pharmaceuticals, Bayer Healthcare Pharmaceuticals

Mintu P Turakhia, MD, MS

- **Research:** Bristol-Myers Squibb, FDA Circulatory System Devices Panel, American Heart Association, Bayer Healthcare Pharmaceuticals, Sanofi
- **Stocks, Board Membership:** 100Plus
- **Employment:** iRhythm Technologies





Thank you!